Translate ideas into impact™
Explore current openings and get ready to prove that impossible isn’t.Unlimit with us™
Jun 26-30, 2022
Absci Senior Scientist Matthew Blankshein will be presenting, “SoluPro® E. coli as a high-performance chassis for drug discovery and scalable production of protein therapeutics” at Biochemical and Molecular Engineering XXII in Cancun, Mexico, June 26-30th. Find more information on the conference website here.
SoluPro® E. coli as a high-performance chassis for drug discovery and scalable production of protein therapeutics
Technologies that involve engineering biological organisms for utilitarian purposes, so-called synthetic biology approaches, are revolutionizing diverse fields such as medicine, industrial manufacturing, and agriculture. Within the biopharmaceutical industry, achieving efficient production and proper folding of therapeutic proteins often presents challenges that impede drug development progress. To this end, Absci has engineered its proprietary SoluPro® E. coli to be an effective host for complex, high-value proteins and is leading the way to smarter, more efficient biologic drug discovery and cell line development. Further enabling this is Absci’s integrated approach to tackle the most challenging protein production problems: 1) the use of quantitative, high throughput assays to collect large-scale genotype-phenotype datasets to identify the best strains, and 2) the use of data-trained AI models to identify and predict genetic configurations that improve protein folding and production. Leveraging these AI models, Absci can rapidly optimize SoluPro® strains for robust production of diverse human-derived and newly engineered proteins, often achieving multiple-fold improvements in the expression of properly folded antibody fragments, full length antibodies, human serum proteins, and hormones, among other targets. Additionally, Absci has Bionic SoluPro® synthetic technologies that enable site-specific incorporation of nonstandard amino acids into target proteins (consequently Bionic™ proteins) during production. These nonstandard amino acids will provide facile means for precise post-translational chemical modifications of the Bionic™ proteins while still achieving desirable yields. Altogether, the combined use of both AI and advanced synthetic biology enables the engineering of bacterial hosts capable of producing proteins with complex folding and disulfide bond arrangements, as well as enabling creation of new Bionic™ protein modalities.
Matthew Blankshein, Senior Scientist, Absci